Abstract

BackgroundIn 2011, we started a cardiovascular (CV) risk management program for rheumatoid arthritis (RA) patients visiting Reade in the Netherlands. We previously reported the presence of under treatment of hypercholesterolemia...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
FRI0759-HPR Collaboration between general practitioners and rheumatologists to manage cardiovascular risk in patients with rheumatoid arthritis patients
P Van Riel ... M Hulscher
Annals of the Rheumatic Diseases | VOL. 76
P Van Riel, et. al.P Van Riel ... M Hulscher
01 Jun 2017
Integrated cardiovascular risk management programme versus usual care in patients at high cardiovascular risk: an observational study in general practice.
Arnoud Wj Van 'T Hof ... Monika Hollander
BJGP open | VOL. 5
Arnoud Wj Van 'T Hof, et. al.Arnoud Wj Van 'T Hof ... Monika Hollander
12 Jan 2021
Male rheumatoid arthritis patients at substantially higher risk for cardiovascular mortality in comparison to women
A.W.R Van Kuijk ... R Hansildaar
Seminars in Arthritis and Rheumatism | VOL. 62
A.W.R Van Kuijk, et. al.A.W.R Van Kuijk ... R Hansildaar
19 Jun 2023
Implementation of a Pharmacist-Directed Cardiovascular Risk and Medication Management Program for Participants in a Construction Trade Benefit Trust Fund
Yifei Liu ... Kathleen Miller
INNOVATIONS in pharmacy | VOL. 1
Yifei Liu, et. al.Yifei Liu ... Kathleen Miller
01 Jun 2010
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers